背景:胰腺脂肪酶是治疗肥胖的重要靶点之一。抑制胰脂肪酶可有效降低脂质吸收,治疗肥胖等相关代谢紊乱。
目的:本研究的目的是采用亲和超滤-高效液相色谱(AUF-HPLC)结合高分辨率抑制谱(HRIP),高效筛选掌叶大黄根和根茎中的胰脂肪酶抑制剂。
方法:使用AUF-HPLC和HRIP筛选掌叶草乙酸乙酯部分中潜在的胰脂肪酶配体和胰脂肪酶抑制剂,分别。所有筛选的化合物均通过HPLC-四极杆飞行时间(Q-TOF)/MS进行鉴定。通过AUF-HPLC和HRIP筛选出8个化合物,用AUF-HPLC或HRIP单独筛选出6种化合物。通过酶抑制实验和分子对接实验验证了所有筛选化合物的胰脂肪酶抑制活性。
结果:发现了五种新的有效胰脂肪酶抑制剂,即原花青素B53,3'-二-O-没食子酸酯(IC50=0.06±0.01μM),1,6-二-O-没食子酰-2-O-肉桂酰基-β-D-葡糖苷(IC50=12.83±0.67μM),1-O-(1,3,5-三羟基)苯基-2-O-没食子酰-6-O-肉桂酰基-β-D-葡糖苷(IC50=17.84±1.33μM),1,2-二-O-没食子酰-6-O-肉桂酰基-β-D-葡糖苷(IC50=18.39±1.52μM),和4-(4'-羟基苯基)-2-丁酮-4'-O-β-D-(2''-O-没食子酰基-6''-O-肉桂酰基)-葡糖苷(IC50=2.91±0.40μM)。发现原花青素B53,3'-二-O-没食子酸酯显示出比阳性对照奥利司他更高的胰脂肪酶抑制活性(IC50=0.12±0.02μM)。
结论:亲和超滤-高效液相色谱(AUF-HPLC)和高分辨率抑制谱(HRIP)的结合可以降低假阴性筛查和漏检的风险,可以更有效地筛选复杂天然产物中的生物活性化合物。
BACKGROUND: Pancreatic lipase is one of the most important key targets in the treatment of obesity. Inhibition of pancreatic lipase can effectively reduce lipid absorption and treat obesity and other related metabolic disorders.
OBJECTIVE: The goal of this study is the efficient screening of pancreatic lipase inhibitors in the root and rhizome of Rheum palmatum using affinity ultrafiltration-high-performance liquid chromatography (AUF-HPLC) combined with high-resolution inhibition profiling (HRIP).
METHODS: Potential pancreatic lipase ligands and pancreatic lipase inhibitors in ethyl acetate fraction of R. palmatum were screened using AUF-HPLC and HRIP, respectively. All screened compounds were identified by HPLC- quadrupole time-of-flight (Q-TOF)/MS. Eight compounds were screened out by both AUF-HPLC and HRIP, and six compounds were screened out by either AUF-HPLC or HRIP alone. The pancreatic lipase inhibitory activities of all screened compounds were verified by enzyme inhibition assay and molecular docking.
RESULTS: Five new potent pancreatic lipase inhibitors were discovered, namely procyanidin B5 3,3\'-di-O-gallate (IC50 = 0.06 ± 0.01 μM), 1,6-di-O-galloyl-2-O-cinnamoyl-β-D-glucoside (IC50 = 12.83 ± 0.67 μM), 1-O-(1,3,5-trihydroxy)phenyl-2-O-galloyl-6-O-cinnamoyl-β-D-glucoside (IC50 = 17.84 ± 1.33 μM), 1,2-di-O-galloyl-6-O-cinnamoyl-β-D-glucoside (IC50 = 18.39 ± 1.52 μM), and 4-(4\'-hydroxyphenyl)-2-butanone-4\'-O-β-D-(2\"-O-galloyl-6\"-O-cinnamoyl)-glucoside (IC50 = 2.91 ± 0.40 μM). It was found that procyanidin B5 3,3\'-di-O-gallate showed higher pancreatic lipase inhibitory activity than the positive control orlistat (IC50 = 0.12 ± 0.02 μM).
CONCLUSIONS: The combination of affinity ultrafiltration-high-performance liquid chromatography (AUF-HPLC) and high-resolution inhibition profiling (HRIP) could reduce the risk of false-negative screening and missed screening and could achieve more efficient screening of bioactive compounds in complex natural products.